Ascent Therapeutics: There's Still Money in Discovery Platforms
This article was originally published in Start Up
Executive Summary
It's a common perception that venture investors have turned their backs-or at least hidden their pocketbooks-from big think platform-based biotechs in search of early stage funding. But a quick look at the large A rounds raised in recent years suggests that sentiment isn't exactly true. Start-ups with promising technologies capable of generating multiple products across a wide swath of therapeutic areas are still gaining funding despite the dearth of capital. One example: Ascent Therapeutics.
You may also be interested in...
Anchor, Ortho-McNeil-Janssen to Collaborate on Peptide Drugs
The J&J subsidiary will pay an undisclosed amount to license drugs on fewer than 10 targets in cancer and metabolic disorders.
Anchor, Ortho-McNeil-Janssen to Collaborate on Peptide Drugs
The J&J subsidiary will pay an undisclosed amount to license drugs on fewer than 10 targets in cancer and metabolic disorders.
Anchor Therapeutics' $10 Million Series B Fund May Grow Based On Near-Term Milestones
The platform company, which targets difficult to drug GPCRs, hopes to announce a Big Pharma collaboration soon, as well as project milestones that prove its worth.